Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Oncology health tech firm Flatiron Health will use Massive Bio’s patient database to identify and recruit participants for ...

On Friday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy ...

The Trump administration’s effort to slash federal funding to universities has found its latest targets, with the government ...